According to Zhitong Finance App News, Nanhua Biotech (000504.SZ) released its report for the third quarter of 2026. The company achieved operating income of 416 million yuan in the first three quarters, an increase of 398.86% over the previous year; net loss attributable to shareholders of listed companies of 2.249,900 yuan; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 4,813,600 yuan; basic earnings per share. The year-on-year increase in the company's revenue was mainly due to the increase in revenue of the new subsidiary Jinhong New Materials in the current period.

According to Zhitong Finance App News, Nanhua Biotech (000504.SZ) released its report for the third quarter of 2026. The company achieved operating income of 416 million yuan in the first three quarters, an increase of 398.86% over the previous year; net loss attributable to shareholders of listed companies of 2.249,900 yuan; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 4,813,600 yuan; basic earnings per share. The year-on-year increase in the company's revenue was mainly due to the increase in revenue of the new subsidiary Jinhong New Materials in the current period.